May 27, 2025 • 8:01 AM EDT XOMA Royalty Purchases Mezagitamab Royalty and Milestone Rights Held by BioInvent International for up to USD $30 Million
May 13, 2025 • 7:30 AM EDT XOMA Royalty Reports First Quarter 2025 Financial Results and Highlights Business Achievements
May 7, 2025 • 7:30 AM EDT XOMA Royalty to Present at H.C. Wainwright 1st Annual Royalty Company Virtual Conference
